Infectious Diseases (all articles)
The COVID-19 vaccine in pregnancy: risks, benefits, and recommendations
4 Feb, 2021 | 01:30h | UTCRelated: Pregnancy, breastfeeding and the SARS-CoV-2 vaccine: an ethics-based framework for shared decision-making AND The Coronavirus Vaccine Presents a Dilemma for Pregnant Women – The New Yorker
Systematic review: No evidence that patients with asthma are at increased risk of COVID-19 diagnosis, hospitalization or death
4 Feb, 2021 | 01:24h | UTC
Randomized trial: Chlorhexidine + alcohol better at prevention of short-term peripheral venous catheter infection compared to iodine + alcohol. Innovative devices were associated with less catheter failure
3 Feb, 2021 | 01:26h | UTC
The AstraZeneca vaccine and over-65s: we may not have all the data yet, but limiting access could be counterproductive
3 Feb, 2021 | 01:46h | UTC
Oxford/AstraZeneca study supports UK decision to delay second doses
3 Feb, 2021 | 01:47h | UTCOxford/AstraZeneca study supports UK decision to delay second doses – Financial Times
Original study (preprint): Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine
See also: Single dose of AstraZeneca vaccine could cut transmission by 67% – The Guardian AND Oxford vaccine could substantially cut spread – BBC
Commentary on Twitter (thread – click for more)
NEW: fresh data from trials in Brazil, South Africa and the UK shows the Oxford/AstraZeneca vaccine is highly effective with a 12 week gap between doses.
Efficacy is in fact much higher with a 12 week interval than a shorter gap
Story by @donatopmancini: https://t.co/PK4NHhGHeH pic.twitter.com/W3urxSECKL
— John Burn-Murdoch (@jburnmurdoch) February 2, 2021
Russia’s Sputnik V COVID-19 vaccine candidate appears safe and is 91.6% effective
3 Feb, 2021 | 01:49h | UTCCommentaries: Sputnik V COVID-19 vaccine candidate appears safe and effective – The Lancet AND Russia’s “Sputnik V” COVID Vaccine Makes Strong 91.6 % Efficacy Showing In Peer-Reviewed Trial Results – Health Policy Watch AND Russia’s COVID vaccine 92% effective, even in those over 60 – CIDRAP AND Russia’s Sputnik V vaccine has 92% efficacy in trial – BBC AND Expert reaction to study looking at preliminary efficacy and safety results from interim analysis of Russian COVID-19 phase 3 vaccine (Sputnik) trial – Science Media Centre
Commentary on Twitter
NEW—Interim analysis of Russian #COVID19 #vaccine phase 3 trial involving nearly 20,000 participants suggests a two-dose regimen has an efficacy of 91.6% against symptomatic #COVID19. No serious adverse events were deemed to be associated with vaccination. https://t.co/40sM7f2nbS pic.twitter.com/Hzrs34uCWr
— The Lancet (@TheLancet) February 2, 2021
Editorial: Coronavirus is in the air — there’s too much focus on surfaces
3 Feb, 2021 | 01:40h | UTCCoronavirus is in the air — there’s too much focus on surfaces – Nature
Related: COVID-19 rarely spreads through surfaces. So why are we still deep cleaning? – Nature
Covid-19: People who have had infection might only need one dose of mRNA vaccine
3 Feb, 2021 | 01:44h | UTCCovid-19: People who have had infection might only need one dose of mRNA vaccine – The BMJ
Original preprint studies: Robust spike antibody responses and increased reactogenicity in seropositive individuals after a single dose of SARS-CoV-2 mRNA vaccine – medRxiv AND Single Dose Vaccination in Healthcare Workers Previously Infected with SARS-CoV-2 – medRxiv
Coronapod: Fixing the world’s pandemic alarm – A year ago the WHO’s coronavirus emergency alarm was largely ignored. Why?
3 Feb, 2021 | 01:43h | UTCCoronapod: Fixing the world’s pandemic alarm – Nature
Observational study: The combination of Immunoglobulins + Methylprednisolone was associated with a better course of fever compared to Immunoglobulins alone in Multisystem Inflammatory Syndrome in children
3 Feb, 2021 | 01:39h | UTC
Commentaries on Twitter
In this cohort study, treatment w IVIG + methylprednisolone was associated w lower risk of treatment failure (defined as fever persistence 2d after start of therapy or fever recrudescence within 7 days) vs IVIG alone among children w MIS-C https://t.co/LjEBFuf33q
— JAMA (@JAMA_current) February 1, 2021
Yes, retrospective, but I find these data interesting as I expect the combined treatment group to be the sicker of the 2
Association of IVIG Plus Methylprednisolone With Persistent or Recurrent Fever in Children With MIS-C https://t.co/Oio8t05zQ1 via @JAMA_current @JAMANetwork
— Joshua Denson MD (@jdensonMD) February 2, 2021
Perspective: We may never get to herd immunity
3 Feb, 2021 | 01:37h | UTCWe May Never Get to Herd Immunity – Think Global Health
Opinion: The Brazil variant is exposing the world’s vulnerability
3 Feb, 2021 | 01:38h | UTCThe Brazil Variant Is Exposing the World’s Vulnerability – The Atlantic
Coccidioidomycosis: a review
2 Feb, 2021 | 01:04h | UTCCoccidioidomycosis: a review – Journal of Investigative Medicine
SARS-CoV-2 evolution and vaccines: cause for concern?
2 Feb, 2021 | 01:27h | UTCSARS-CoV-2 evolution and vaccines: cause for concern? – The Lancet
Commentaries on Twitter
Just to show how fast things are moving
On the same day this was published
"#SARSCoV2 evolution and vaccines: cause for concern?"@LancetRespirMed https://t.co/YE3J6tSMRV
The ? was answered, w/ a drop-off in vaccine efficacy (89%->49%) for B.1.351, (96%->86%) for B.1.1.7— Eric Topol (@EricTopol) January 31, 2021
✨✨The overall effectiveness of immunisation will correlate with rates of vaccine uptake
The ⬆️ the proportion of a population vaccinated,the ⬇️ the number of susceptible individuals, and the fewer opportunities SARS-CoV-2 will have to spread & mutate✨✨ https://t.co/hxOCkTXyB6— Antibiotic Steward? Bassam Ghanem (@ABsteward) January 31, 2021
Covid-19: WHO warns against “vaccine nationalism” or face further virus mutations
2 Feb, 2021 | 01:30h | UTCCovid-19: WHO warns against “vaccine nationalism” or face further virus mutations – The BMJ
Perspective: Are we expecting too much from our COVID-19 vaccines?
2 Feb, 2021 | 01:26h | UTCAre We Expecting Too Much from Our COVID-19 Vaccines? – HIV and ID Observations
Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant
2 Feb, 2021 | 01:29h | UTC
Commentary on Twitter
The SARS-CoV-2 vaccine produced by Novavax is 95.6% effective against the original variant of SARS-CoV-2 but also provides protection against the newer variants B.1.1.7 (85.6%) and B.1.351 (60%), preliminary data from clinical trials show https://t.co/lhsB2UzD08
— The BMJ (@bmj_latest) February 1, 2021
Variants, 3 new Covid vaccines, and contested efficacy claims: A month of seismic shifts and confusion
2 Feb, 2021 | 01:25h | UTC
Post severe COVID-19, CT reveals potentially lifetime lung damage in one-thirds of patients
2 Feb, 2021 | 01:19h | UTCOriginal Study: Six-Month Follow-up Chest CT findings after Severe COVID-19 Pneumonia – Radiology
COVID-19 rarely spreads through surfaces. So why are we still deep cleaning?
2 Feb, 2021 | 01:20h | UTCCOVID-19 rarely spreads through surfaces. So why are we still deep cleaning? – Nature
COVID-19 vaccine-linked adenopathies could mimic breast malignancies
2 Feb, 2021 | 01:17h | UTCCOVID-19 Vaccine-Linked Adenopathies Could Mimic Breast Malignancies – Diagnostic Imaging
Original Study: Unilateral axillary Adenopathy in the setting of COVID-19 vaccine – Clinical Imaging
Commentaries on Twitter
Important for radiologists to consider vaccine induced hyperplastic adenopathy in unilateral axillary adenopathy seen on #breastimaging post #COVID19Vaccine #COVID19
Read here https://t.co/7IizHgIzU0@NishiMehtaMD @KatiaDodelzon @KemiMDRad @WCMRadiology @BreastImaging
— Clinical Imaging (@CI_Journal) January 19, 2021
The COVID-19 vaccine may cause swollen lymph nodes that could be mistaken for breast malignancies. However, it's important not to postpone your vaccine or breast cancer screenings, researchers from @WCMRadiology and @WCMBreastCenter say. https://t.co/jLuVbA2rXL
— Weill Cornell Medicine (@WeillCornell) January 22, 2021
Study estimates vaccines against 10 pathogens prevented 37 million deaths in low- and middle-income countries in the last 20 years
1 Feb, 2021 | 01:44h | UTCCommentaries: Vaccines work: a reason for celebration and renewed commitment – The Lancet AND Study estimates that, without vaccination against 10 diseases, mortality in children under five would be 45% higher in low-income and middle-income countries – The Lancet AND Vaccines against 10 diseases prevented 37 million deaths in low- and middle-income countries in the last 20 years – London School of Hygiene & Tropical Medicine
Commentary on Twitter
NEW—Study estimates from 2000-2030, #vaccination against 10 major pathogens will have prevented 69 million deaths in low/middle-income countries (LMICs). Without vaccination, mortality in children under 5 would be 45% higher in LMICS. Read: https://t.co/S4JXOqdctU pic.twitter.com/MF8W25nDJJ
— The Lancet (@TheLancet) January 28, 2021
[Not published yet] Full-dose Heparin best for moderate COVID-19 regardless of D-dimer — Data released from ACTIV-4a, ATTACC, and REMAP-CAP trials
1 Feb, 2021 | 01:58h | UTCFull-Dose Heparin Best for Moderate COVID-19 Regardless of D-dimer — Data released from ACTIV-4a, ATTACC, and REMAP-CAP trials – MedPage Today (free registration required)
Trial results: ATTACC, ACTIV-4a & REMAP-CAP multiplatform RCT Results of interim analysis – ATTACC Trial
New Updates to the Surviving Sepsis Campaign COVID-19 Guidelines
1 Feb, 2021 | 01:56h | UTCAdditional resources: COVID-19 Guidelines – Surviving Sepsis Campaign
Commentary on Twitter
New updates to the #SurvivingSepsis Campaign #COVID19 Guidelines! Includes new recommendations for therapeutics and defines severe vs critical COVID-19.
View the full update in @CritCareMed, more infographics, and recommendations table here: https://t.co/OUuOwGJCR4#SCCMSoMe pic.twitter.com/1RGckdvoIm
— SCCM (@SCCM) January 30, 2021
Analysis: J&J and Novavax Data
1 Feb, 2021 | 01:54h | UTCJ&J and Novavax Data – In the Pipeline